For University Technology Transfer Offices
The same MD + biomedical-engineer, fully-cited diligence your licensees' VCs run — offered to every disclosure in your program as a per-cohort annual license that folds into your grant and program budgets.
Or email arvind@vantagebiomed.com directly
Most university inventions never reach the patients they could help. A busy TTO faces more invention disclosures each year than it has clinical and commercial bandwidth to evaluate. Vantage embeds into your program as a per-cohort license — every disclosure gets a cited, physician + engineer risk read in 48 hours, so you know which technologies to license, develop, or pass on.
Batch Pipeline Screening
Watch Vantage transform an unscored pipeline into ranked, actionable intelligence
| Company | Score | Status |
|---|
Your Biggest Challenges, Solved
The Vantage Index provides an objective, quantified ranking across your entire portfolio. Instead of gut-feel prioritization, you get data-driven triage. Technologies scoring 70+ are investor-ready; 50-69 need targeted development; below 50 need fundamental pivots.
Every score comes with a board-ready summary. Show leadership exactly where each technology stands, with performance metrics mapped to the categories AUTM's annual survey tracks — license agreements executed, startups formed, active licenses.
The Vantage Index becomes a credibility asset. When your spin-out approaches VCs with a third-party clinical adoption score of 75+, it signals a level of independent diligence peer TTOs can't demonstrate — a fully cited read the founder can put in front of investors.
That's exactly what we provide. Our MD + BME team evaluates the same categories that VC investors will scrutinize, so your spin-outs are prepared before they ever take a meeting.
Every cohort dashboard includes performance metrics mapped to AUTM survey categories: license agreements executed, startup companies formed, cumulative active licenses. The Vantage Index adds a comparative layer that AUTM metrics alone can't provide — not just what happened, but how comparable companies fared.
AUTM's annual Licensing Activity Survey is the standard benchmark for U.S. academic technology transfer. Commercialization is a multi-year process, and only a fraction of invention disclosures ever become licensed products — so it matters that scarce resources go to the disclosures most likely to clear that path. Vantage gives you a cited, comparative read at the disclosure stage to help make that call.
Use Cases
Evaluate disclosures before committing patent prosecution resources. Our assessment identifies which have viable commercialization pathways — saving $15K-50K per abandoned filing.
Get your most promising technologies investor-ready. A 70+ Vantage Index tells VCs your spin-out has been independently validated.
Every assessment includes an executive summary suitable for university leadership and advisory boards. Show exactly where each technology stands with AUTM-benchmarked metrics.
Pricing for TTOs
Lead with a per-cohort annual license that folds into your SBIR/STTR, NIH, and state economic-development grant budgets. Single-technology assessments remain available as a one-off option.
Vantage embedded in your program — every disclosure gets a cited MD + BME risk read your licensees' VCs would recognize. Designed to fold into SBIR/STTR technical-assistance, NIH, and state economic-development grant budgets.
Full-program integration for high-volume offices — every disclosure screened, monitored, and re-scored across the year, folded into your grant and program budgets.
Prefer to start with a single disclosure? A one-off assessment with commercialization viability, patent prosecution guidance, and licensee attractiveness. Includes 30-minute debrief with Dr. Ravinutala and Aswini Ravinutala, BME.
Custom programs available. Contact us →
Quick Screens with wide confidence bands on key assessment dimensions are strong candidates for TTO Score upgrade ($7,500) — adding comprehensive narrative insights, patent prosecution guidance, and a 30-minute expert debrief.
All programs accept purchase order billing and are compatible with university procurement workflows. Program licenses are designed to fold into SBIR/STTR technical-assistance funds, NIH, and state economic-development grant budgets — and our assessments strengthen the technical-merit and commercialization narratives in those applications.
Built for Technology Transfer
An outside clinical + engineering read on each disclosure — which inventions have genuine commercial and investor legs, and which face regulatory or reimbursement walls — without building an internal review team.
A defensible, documented triage framework you can put in front of your board and faculty: every call grounded in cited public data, not opinion.
A 48-hour turnaround per disclosure, so licensing decisions don't wait on scarce internal clinical and engineering bandwidth.
Illustrative TTO Scenario
How a TTO could use Vantage to guide licensing strategy
Transparency note: This is an illustrative walkthrough, not a paid engagement — it shows the kind of licensing-strategy output an assessment produces. We’ll cite real client work by name when sponsors permit.
TTO Score
The Situation: A research university had a materials science invention with potential applications across medical devices, wound care, and hospital infrastructure. The faculty inventor was funded to develop a prototype, and the TTO needed guidance on commercialization strategy.
What Vantage Identified
Identified that the device pathway (510(k)) was most viable for first commercialization, while the drug-device combination pathway would require significantly more investment and timeline extension.
Score also identified 3 existing licensees in adjacent spaces and recommended a non-exclusive licensing strategy to preserve optionality across all three application domains (devices, wound care, infrastructure).
TTO Action & Outcome
The TTO structured a non-exclusive licensing agreement that preserved optionality across all three application domains. First licensee took the device pathway; second licensee took wound care; third licensee handled infrastructure licensing.
This multi-licensee strategy was designed to capture value across all three application domains rather than lock into a single exclusive deal — avoiding the "wrong choice" trap that leaves value on the table.
Deliverables
Every TTO assessment includes an executive summary for leadership and board review. Here's what a real technology evaluation looks like.
See a Sample Evaluation →Designed for Academic Procurement
From PO to payment — no complex vendor onboarding required.
We work directly with university procurement offices. Standard PO process, NET-30/NET-60 terms, W-9 on file. No complex vendor onboarding required — we integrate into your existing purchasing workflows.
Our cohort licensing model fits within existing TTO operating budgets. A single PO covers your entire cohort assessments — no per-company approvals needed. Simplified budget allocation, faster procurement approval.
We provide complete sole source justification documentation. Our specialized MD + BME clinical adoption framework has no direct comparable in the market. We streamline the procurement documentation your office needs.
Assessments can be charged to SBIR/STTR supplements, I-Corps budgets, or institutional matching funds. We provide the documentation your grants office needs for compliance and reporting.
Our procurement team can expedite your renewal paperwork, coordinate with your university's vendor management system, and ensure NET terms align with your fiscal calendar.
Contact Our Procurement TeamEvery assessment is delivered under our standard engagement terms, with reperformance or refund as the remedy if a deliverable does not conform to the agreed scope. Our work product reflects independent, physician-led, engineer-built diligence — not investment advice and not a guarantee of outcomes.
Cohort-anchored differentiator analysis with effect-size disclosure across 800+ outcome-labeled biomedical companies in our proprietary cohort substrate, growing with every engagement
Your Assessment Team
Led by Dr. Arvind Ravinutala (MD, practicing physician) and Aswini Ravinutala (BME, 8+ years medical device engineering, ex-Axonics/Boston Scientific). Meet the full team →
Portfolio Triage
Score your entire disclosure backlog. Know which technologies to license, which to develop, and which to pass on.
Use our Deal Flow Evaluation service to assess your full invention disclosure pipeline at once. Submit your disclosures and receive ranked assessments with commercial viability scores and development pathway recommendations in 24–48 hours. Quick Screen is $5,000 per technology with bulk discounts (10% off 5+, 15% off 10+, 20% off 20+) — as low as $4,000 per technology at 20+ disclosures.
Use case: Your TTO receives 50-100 invention disclosures per year. Score them all systematically to identify the technologies best positioned for commercialization on documented risk factors, then focus licensing and development resources accordingly.
Embed Vantage as a per-cohort license that folds into your grant budgets — every disclosure gets a cited, physician + engineer risk read. Prefer to start small? A single-technology assessment is available too.
In a free call, we'll discuss how to embed Vantage in your program and which license fits your grant and program budgets.